A discussion of the disease state, current therapies, and treatment challenges in ER+/HER2- metastatic breast cancer.
Emergent Advances and Subgroup Data in ER+, HER2- Metastatic Breast Cancer from SABCS 2023
EP. 2: EMERALD Subgroup Analysis in Patients With Visceral and Bone Metastases: Clinical Implication
A comprehensive review of the safety, efficacy, and subgroup analysis of the EMERALD Trial.
Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.
Current treatment landscape in ER+/HER2- metastatic breast cancer and unmet needs in overcoming treatment resistance.
Dr. Hope Rugo discusses EMERALD subgroup analysis, safety, and efficacy in patients with coexisting resistance mutations.
Expert insights on improving outcomes in ER+/HER2- metastatic breast cancer patients with resistance mutations.
Dr. Paolo Tarantino discusses the current treatment landscape of ER+/HER2- low metastatic breast cancer and unmet needs.
A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.
Dr. Paolo Tarantino offers expert guidance on optimizing outcomes for patients with ER+/HER2-low metastatic breast cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
